Hypercoagulability and thrombotic events in severe SARS-CoV-2 infections
DOI:
https://doi.org/10.33448/rsd-v12i11.43772Keywords:
COVID-19; Hypercoagulability; SARS-CoV-2; Thrombosis.Abstract
COVID-19 pathology caused by SARS-CoV-2 virus infection manifests mainly with respiratory tract symptoms. However, several studies demonstrate characteristics of a systemic disease with repercussions on the cardiovascular, respiratory, gastrointestinal, neurological, hematopoietic and immunological systems. In the homeostasis process, coagulation represents a defense mechanism of the body, however in some individuals there is an exacerbation of this process, giving rise to complications correlated with hypercoagulability and thromboembolic events. This is an integrative review of the literature through data extraction, analysis, synthesis of results and conclusion of articles already published between the years 2020 and 2023. The following databases were used: Lilacs, PubMed, IBECS and MedLine by through the virtual health library. The objective of the work is to carry out an analysis through reviews of scientific articles on the relationship between the hypercoagulable state in patients with severe SARS-CoV-2, given that there is a relatively high incidence of thrombotic and thromboembolic events as a complication of the disease. It is understood that infection with the virus that causes COVID-19 can lead to a state of hypercoagulability, in which there is an increase in serum levels of fibrinogen, D-dimer and some coagulation factors, favoring thromboembolic events, which highlights the need research, prevention and treatment of these, as they present high morbidity and mortality.
References
Abou-Ismail, M. Y., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L. (2020). The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thrombosis research, 194, 101-115. https://doi.org/10.1016/j.thromres.2020.06.029
Acharya, Y., Alameer, A., Calpin, G., Alkhattab, M., & Sultan, S. (2022). A comprehensive review of vascular complications in COVID-19. Journal of Thrombosis and Thrombolysis, 1-8. https://doi.org/10.1007/s11239-021-02593-2
Chan, N., & Eikelboom, J. (2021). Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality? European Heart Journal, 42(33), 3143-3145. https://doi.org/10.1093/eurheartj/ehab417
Chowdary, P. (2022). COVID‐19 coagulopathy–what should we treat? Experimental Physiology, 107(7), 749-758. https://doi.org/10.1113/EP089404
Corey, K. M., Olson, L. B., Naqvi, I. A., Morrison, S. A., Davis, C., Nimjee, S. M., & Sullenger, B. A. (2022). Suppression of fibrinolysis and hypercoagulability, severity of hypoxemia, and mortality in COVID-19 patients: A retrospective cohort study. Anesthesiology, 137(1), 67-78. https://doi.org/10.1097/ALN.0000000000004239
Fan, B. E., Umapathi, T., Chua, K., Chia, Y. W., Wong, S. W., Tan, G. W. L., & Dalan, R. (2021). Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients. Journal of thrombosis and thrombolysis, 51, 971-977. https://doi.org/10.1007/s11239-020-02332-z
Gerber, G. F., & Chaturvedi, S. (2021). How to recognize and manage COVID-19-associated coagulopathy. Hematology, 2021(1), 614-620. https://doi.org/10.1182/hematology.2021000297
Hanff, T. C., Mohareb, A. M., Giri, J., Cohen, J. B., & Chirinos, J. A. (2020). Thrombosis in COVID‐19. American journal of hematology, 95(12), 1578-1589. https://doi.org/10.1002/ajh.25982
Hottz, E. D., & Martins-Gonçalves, R. Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19. Blood Adv. 2022; 6 (17): 5085–99. https://doi.org/10.1182/bloodadvances.2021006680
Ichikawa, J., Okazaki, R., Fukuda, T., Ono, T., Ishikawa, M., & Komori, M. (2022). Evaluation of coagulation status using clot waveform analysis in general ward patients with COVID-19. Journal of Thrombosis and Thrombolysis, 1-5. https://doi.org/10.1007/s11239-021-02499-z
Jayarangaiah, A., Kariyanna, P. T., Chen, X., Jayarangaiah, A., & Kumar, A. (2020). COVID-19-associated coagulopathy: an exacerbated immunothrombosis response. Clinical and Applied Thrombosis/Hemostasis, 26, 1076029620943293. https://doi.org/10.1177/1076029620943293
Kreidieh, F., & Temraz, S. (2021). Anticoagulation for COVID-19 patients: a bird's-eye view. Clinical and Applied Thrombosis/Hemostasis, 27. https://doi.org/10.1177/10760296211039288
Li, M., Gitarts, S., Nyabera, A., Kondaveeti, R., Hammudeh, Y., Gonzalez, C., ... & Rahman, H. (2022). Continuous infusion low-dose unfractionated heparin for the management of hypercoagulability associated with COVID-19. Journal of Pharmacy Practice, 35(2), 205-211. https://doi.org/10.1177/0897190020966207
Manzur-Pineda, K., O’Neil, C. F., Bornak, A., Lalama, M. J., Shao, T., Kang, N., ... & Rey, J. (2022). COVID-19-related thrombotic complications experience before and during delta wave. Journal of Vascular Surgery, 76(5), 1374-1382. https://doi.org/10.1016/j.jvs.2022.04.053
Munoz-Rivas, N., Abad-Motos, A., Mestre-Gomez, B., Sierra-Hidalgo, F., Cortina-Camarero, C., Lorente-Ramos, R. M., ... & Infanta Leonor Thrombosis Research Group. (2021). Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study. Thrombosis research, 199, 132-142. https://doi.org/10.1016/j.thromres.2020.12.024
Pastori, D., Cormaci, V. M., Marucci, S., Franchino, G., Del Sole, F., Capozza, A., & Pignatelli, P. (2023). A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. International Journal of Molecular Sciences, 24(4), 3169. https://doi.org/10.3390/ijms24043169
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica, 6, 93-100.
Ragnoli, B., Da Re, B., Galantino, A., Kette, S., Salotti, A., & Malerba, M. (2023). Interrelationship between COVID-19 and coagulopathy: pathophysiological and clinical evidence. International Journal of Molecular Sciences, 24(10):8945. https://doi.org/10.3390/ijms24108945
Sharma, M., & Surani, S. (2020). Revisiting one of the dreaded outcomes of the current pandemic: pulmonary embolism in COVID-19. Medicina, 56(12), 670. https://doi.org/10.3390/medicina56120670
Violi, F., Pastori, D., Cangemi, R., Pignatelli, P., & Loffredo, L. (2020). Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge. Thrombosis and haemostasis, 120(06), 949-956. https://doi.org/10.1055/s-0040-1710317
Wada, H., Shiraki, K., Shimpo, H., Shimaoka, M., Iba, T., & Suzuki-Inoue, K. (2023). Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019. International Journal of Molecular Sciences, 24(9), 7975. https://doi.org/10.3390/ijms24097975
Warkentin, T. E., & Kaatz, S. (2020). COVID-19 versus HIT hypercoagulability. Thrombosis research, 196, 38-51. https://doi.org/10.1016/j.thromres.2020.08.017
Xie, J., Prats-Uribe, A., Feng, Q., Wang, Y., Gill, D., Paredes, R., & Prieto-Alhambra, D. (2022). Clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory patients with COVID-19. JAMA internal medicine, 182(10), 1063-1070. https://doi.org/10.1001/jamainternmed.2022.3858
Xiang, M., Jing, H., Wang, C., Novakovic, V. A., & Shi, J. (2022). Persistent lung injury and prothrombotic state in long COVID. Frontiers in Immunology, 13, 862522. https://doi.org/10.3389/fimmu.2022.862522
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Túlio Takeo Prado Sato; Kaynan Marques de Camargo; Luis Gustavo Peron Martins; Paulo Fenelon Marinho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
